AIMC Topic: Inflammatory Bowel Diseases

Clear Filters Showing 81 to 90 of 114 articles

Classification of Paediatric Inflammatory Bowel Disease using Machine Learning.

Scientific reports
Paediatric inflammatory bowel disease (PIBD), comprising Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBDU) is a complex and multifactorial condition with increasing incidence. An accurate diagnosis of PI...

Evaluation of supervised machine-learning algorithms to distinguish between inflammatory bowel disease and alimentary lymphoma in cats.

Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
Inflammatory bowel disease (IBD) and alimentary lymphoma (ALA) are common gastrointestinal diseases in cats. The very similar clinical signs and histopathologic features of these diseases make the distinction between them diagnostically challenging. ...

Machine Learning Meta-analysis of Large Metagenomic Datasets: Tools and Biological Insights.

PLoS computational biology
Shotgun metagenomic analysis of the human associated microbiome provides a rich set of microbial features for prediction and biomarker discovery in the context of human diseases and health conditions. However, the use of such high-resolution microbia...

Linking rare and common disease: mapping clinical disease-phenotypes to ontologies in therapeutic target validation.

Journal of biomedical semantics
BACKGROUND: The Centre for Therapeutic Target Validation (CTTV - https://www.targetvalidation.org/) was established to generate therapeutic target evidence from genome-scale experiments and analyses. CTTV aims to support the validity of therapeutic t...

The rate of mucosal healing by azathioprine therapy and prediction by artificial systems.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
BACKGROUND/AIMS: We aimed to assess the effect of azathioprine on mucosal healing in patients with inflammatory bowel diseases (IBD). Artificial neural networks were applied to IBD data for predicting mucosal remission.

Fecal gut microbiota and amino acids as noninvasive diagnostic biomarkers of Pediatric inflammatory bowel disease.

Gut microbes
BACKGROUND AND AIMS: Fecal calprotectin (FCP) has limited specificity as diagnostic biomarker of pediatric inflammatory bowel disease (IBD), leading to unnecessary invasive endoscopies. This study aimed to develop and validate a fecal microbiota and ...

Deep learning-based detection of bacterial swarm motion using a single image.

Gut microbes
Motility is a fundamental characteristic of bacteria. Distinguishing between swarming and swimming, the two principal forms of bacterial movement, holds significant conceptual and clinical relevance. Conventionally, the detection of bacterial swarmin...

Addressing bias in biomarker discovery for inflammatory bowel diseases: A multi-faceted analytical approach.

International immunopharmacology
Xiang-Guang et al. investigate the identification of novel biomarkers linked to M1 macrophage infiltration in inflammatory bowel diseases (IBD). Utilizing advanced bioinformatics and machine learning techniques, the researchers developed predictive m...

From traditional to artificial intelligence-driven approaches: Revolutionizing personalized and precision nutrition in inflammatory bowel disease.

Clinical nutrition ESPEN
Inflammatory bowel disease (IBD), comprising ulcerative colitis and Crohn's disease, is a chronic inflammatory condition with global prevalence and varying incidence. The IBD pathogenesis involves intricate interactions among genetic, host and enviro...

Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
BACKGROUND AND AIMS: Real-world studies on vedolizumab in inflammatory bowel disease (IBD) are often limited by small sample size and short follow-up. In this study, we investigated the 2-year effectiveness and safety of vedolizumab in patients with ...